294 related articles for article (PubMed ID: 19843396)
1. The development of albendazole for lymphatic filariasis.
Horton J
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396
[TBL] [Abstract][Full Text] [Related]
2. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
Hooper PJ; Bradley MH; Biswas G; Ottesen EA
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
[TBL] [Abstract][Full Text] [Related]
3. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
Gustavsen KM; Bradley MH; Wright AL
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S11-5. PubMed ID: 19843393
[TBL] [Abstract][Full Text] [Related]
4. The role of albendazole in programmes to eliminate lymphatic filariasis.
Ottesen EA; Ismail MM; Horton J
Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
Anto F; Asoala V; Anyorigiya T; Oduro A; Adjuik M; Akweongo P; Aborigo R; Bimi L; Amankwa J; Hodgson A
Trop Med Int Health; 2011 Sep; 16(9):1112-9. PubMed ID: 21689221
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Horton J; Witt C; Ottesen EA; Lazdins JK; Addiss DG; Awadzi K; Beach MJ; Belizario VY; Dunyo SK; Espinel M; Gyapong JO; Hossain M; Ismail MM; Jayakody RL; Lammie PJ; Makunde W; Richard-Lenoble D; Selve B; Shenoy RK; Simonsen PE; Wamae CN; Weerasooriya MV
Parasitology; 2000; 121 Suppl():S147-60. PubMed ID: 11386686
[TBL] [Abstract][Full Text] [Related]
7. Elimination of lymphatic filariasis: do we have the drugs to complete the job?
Bockarie MJ; Deb RM
Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694
[TBL] [Abstract][Full Text] [Related]
8. Elimination of transmission of lymphatic filariasis in Egypt.
Molyneux DH
Lancet; 2006 Mar; 367(9515):966-8. PubMed ID: 16564345
[No Abstract] [Full Text] [Related]
9. Lymphatic filariasis and Brugia timori: prospects for elimination.
Fischer P; Supali T; Maizels RM
Trends Parasitol; 2004 Aug; 20(8):351-5. PubMed ID: 15246315
[TBL] [Abstract][Full Text] [Related]
10. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
11. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
Babu BV; Kar SK
Trop Med Int Health; 2004 Jun; 9(6):702-9. PubMed ID: 15189460
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Babu BV; Rath K; Kerketta AS; Swain BK; Mishra S; Kar SK
Trans R Soc Trop Med Hyg; 2006 May; 100(5):464-9. PubMed ID: 16288792
[TBL] [Abstract][Full Text] [Related]
13. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
[TBL] [Abstract][Full Text] [Related]
14. Is anthelmintic resistance a threat to the program to eliminate lymphatic filariasis?
McCarthy J
Am J Trop Med Hyg; 2005 Aug; 73(2):232-3. PubMed ID: 16103580
[No Abstract] [Full Text] [Related]
15. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
[TBL] [Abstract][Full Text] [Related]
16. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
[No Abstract] [Full Text] [Related]
17. [Lymphatic filariasis].
Sante; 2000; 10(5):360-1. PubMed ID: 11221698
[No Abstract] [Full Text] [Related]
18. Recent advances in the chemotherapy of lymphatic filariasis.
Navaratnam V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 2():51-4. PubMed ID: 7973948
[TBL] [Abstract][Full Text] [Related]
19. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
Weil GJ; Jacobson JA; King JD
Int Health; 2020 Dec; 13(Suppl 1):S60-S64. PubMed ID: 33349879
[TBL] [Abstract][Full Text] [Related]
20. Mass drug administration to treat lymphatic filariasis.
Ravindran B
Lancet; 2002 Jun; 359(9321):1948. PubMed ID: 12057582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
